177Lu-PSMA-617 With Liver Directed Therapy in Metastatic Castration Resistant Prostate Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2030-08-31
Target enrollment:
Participant gender:
Summary
This is an open label, single arm, phase 1b study to determine the safety of combining sequential Prostate-Specific Membrane Antigen (PSMA)-targeted 177Lu-PSMA-617 radionuclide therapy with liver-directed therapy in metastatic castrate-resistant prostate cancer (mCRPC) patients with liver metastases amenable to liver-directed therapy who have progressed on at least one prior androgen pathway inhibitor.
Phase:
PHASE1
Details
Lead Sponsor:
University of California, San Francisco
Collaborator:
Novartis
Treatments:
Biopsy Lutetium-177 Magnetic Resonance Spectroscopy Pluvicto Surveys and Questionnaires